Review Tuesday, September 7

The growth of Nordic life sciences, investment opportunities, healthtech innovation and more. 

All time in CET (EET = +1hr / BST = -1hr / EST = -6hr)

09:00 LSX Welcome

Josh Dance, SVP, LSX

Josh Dance, SVP, LSX

09:10 Keynote Presentation: How Nasdaq Nordics Markets are Driving Growth Capital for Nordic Life Sciences

Adam Kostyal, SVP, Nasdaq

Adam Kostyal, SVP, Nasdaq (moderator)

10:00 Keynote Panel: Nordic Life Sciences, Further Globally Recognised – What’s Next for the Thriving Ecosystem?

Whilst a challenging year for many reasons,2020 felt like a step change for the Nordics, putting an already attractive region even more firmly on the map. A number of companies passed significant private and public fundraising, clinical and company development milestones, and these positives stories continued through into 2021.

While the life sciences and healthcare industry was put ever-more under focus, in the Nordics particularly the increased capital flow and interest from international investors, pharma and other key stakeholders interested in playing their part to continue to build the maturing Nordic ecosystem was clear to see. What is next for the sector as a whole and how are these companies planning to grow, develop and internationalise further?

  • Stories of success in a time of isolation – how have companies passed key milestones while connections are harder?
  • Which models have been adopted for building companies – local and organic growth vs. more rapid global expansion?
  • What next for the Nordic regions next-wave life science leaders?

Martin Welschof, CEO, BioInvent 
Mai-Britt Zocca, CEO, IO Biotech 
Anders Martin-Löf, CFO, Oncopeptides 
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics 

Martin Welschof, CEO, BioInvent 300x    Mai-Britt Zocca, CEO, IO Biotech    Anders Martin-Löf, CFO, Oncopeptides    Renee-Aguiar-Lucander--CEO--Calliditas-Therapeutics-ConvertImage-1

11:00 Presentation & Panel: Success in Investment in the Nordics and Europe – Time to Recalibrate?

While challenges, opportunities and focus areas for investment are often discussed at length, what does analysis of key wider industry trends tell us about the true dynamics of European life sciences investment, and how it’s changing? Leading Nordic and European investors discuss what learnings can investors and companies alike take from key investment metrics.

  • Do ever-increasing larger financing rounds really mean venture multiples talked about are a realistic outcome in European life sciences investments?
  • How dependent is the European life sciences venture capital dependant on well-functioning public markets? How useful is it to benchmark with the US system?
  • With increased US capital into early-stage European life sciences, will these dynamics shift?
  • When do PIPEs and VCs making investments in public companies make sense, for the companies and investors? Is this an untapped opportunity for the large cohort of public Nordic life sciences companies?

Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures 
Søren Moller, Managing Partner, Novo Seeds 
Ann-Tove Kongsnes, Investment Director, Investinor 
Ingrid Teigland Akay, Managing Partner, Hadean Ventures 
Moderator: Tony Proctor, Partner, Potter Clarkson

Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures    Soren Moller    Ann-Tove Kongsnes, Investment Director, Investinor    Ingrid Teigland Akay, Managing Partner, Hadean Ventures    Tony Proctor, Partner, Potter Clarkson

13:00 Masterclass: How to Optimize Biotech Drug Development Delivery Strategy

Strategic partnerships now play an increasing role in transforming the drug development process. A more structured, yet tailored approach combines acceleration with improved quality and compliance and allows for better insights and decision making. Effective partnerships are those that fit with both party’s needs, at the right times, and in the most suitable way, and this is key to the biotech’s success. This session presents a case study and lessons that cab be learned from the effective collaboration along the drug development journey between a CRO and a biotech company.

Luke Gill, VP Clinical Development Services, TFS HealthScience
David Bejker, CEO, Affibody

Luke Gill, VP Clinical Development Services, TFS Health Science    David Bejker, CEO Affibody

14:00 Panel: Leading European Healthtech Innovation – Investment, Expansion and Internationalisation

While the wider European healthtech market is booming, the Nordics has become a frontrunner in digital innovation in healthcare. Nordic digital health and healthech innovation is gaining massive traction and attracting major investment. What has been key to this success and what is needed to secure the region as a globally competitive digital health innovation hub?

  • How has the Nordic region built such an innovative an internationally competitive digital ecosystem?
  • Investment trends in the healthtech – will the capital keep flowing, and what do investors need to see to fund the next generation of innovation?
  • What are the next steps for the regions leading healthtech businesses in further expansion and internationalisation?

Anna-Karin Edstedt Bonamy, CEO, Doctrin 
Jonas Hjortshøj, CCO, Liva Healthcare
John Drakenberg Renander, CEO, Alex Therapeutics
Eric Teder, Country Manager Sweden,

Anna-Karin Edstedt Bonamy, CEO, Doctrin 300x    Jonas Hjortshøj, CCO, Liva Healthcare    John Drakenberg Renander, CEO, Alex Therapeutics    Eric Teder, Operations Director and Country Manager Sweden,

15:00 Presentation: Global Registrations – Synergies Between US and Europe Medical Device Registration

  • Planning your development activities so that documentation and generated data can be used in submissions
  • Key considerations when planning FDA submission straight from CE mark
  • Which first? Pros and cons of targeting FDA approval or CE mark first
  • With FDA approval in place, what can be recycled for CE mark?
  • An integrated look at clinical strategy to fulfil RA needs in both EU and US

Jan Bart Hak, Head of Medical Device Department, ProPharma Group 

Jan Bart Hak, Head Medical Device Department, ProPharma Group    

16:00 Panel: Preparing for and Executing Successful Cross-Border Transactions

Life sciences is a global industry and cross-border deals are often critical for growth and internationalisation plans. Scientific, market, structural and cultural challenges are all key considerations in successful licencing, partnering or M&A deal across borders. Executives explore the optimal means of preparation of materials, readiness with relevant data and planning, as well as the pitfalls in these critical endeavours.

  • Starting dialogues and creating partnerships - what needs to be in place, anticipated and planned early to be successful?
  • What are the most common challenges and pitfalls companies face in executing transactions and international partnerships?
  • Europe, the US and beyond – building a long-term global strategy

Søren Bregenholt, CEO, Alligator Bioscience 
Magnus Corfitzen, CEO, Ascelia Pharma 
Gunilla Oswald, CEO, BioArctic 
Nathalie ter Wengel, European Lead Worldwide Business Development, Pfizer 
Moderator: Greg Benning, Managing Director, Back Bay Life Science Advisors 

Søren Bregenholt, CEO, Macrophage 300x    Magnus Corfitzen, CEO, Ascelia Pharma    Gunilla Oswald, CEO, BioArctic    Nathalie Ter Wengel 300x    Greg Benning

17:00 Video Networking Reception